Dr Reddyrsquo

Rediff.com » News » Dr Reddyrsquo

News for Dr Reddyrsquo

News
Business
Movies

Covid vaccine could cost up to Rs 1000 in private market

While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private......

Expert panel seeks more data on Sputnik V Covid vaccine

‘No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting’ IMAGE:......

Sputnik V vaccine may be added to India's Covid armoury soon

‘We expect to get the approval in the next few weeks,’ says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy’s Laboratories (DRL). IMAGE: Medics administer the first......

COVID-19 vaccines likely to have longer shelf life

A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval,......

Cipla to price Remdesivir for Covid-19 under Rs 5,000

Hetero has priced the injectable drug at Rs 5,400 per 100 mg vial. With more drugmakers in line to launch the drug soon, the prices may see a further erosion. Sohini Das reports. IMAGE: An......

Upper-teens EPS growth likely for Gland Pharma in next two financial yrs

Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. Gland Pharma's......

Lower input costs may aid pharma firms' Q2 margins

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and......

BSE 100 companies boost R&D, innovation challenges persist

Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period......

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

Dr Reddy’s Laboratories (DRL) is set to acquire Haleon’s global portfolio of consumer healthcare brands in the nicotine replacement therapy (NRT) category outside of the US.......

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. Illustration: Uttam......

Review: Azhar is a bland, badly-set souffl of Bollywood tropes without a soul

Who was Mohammad Azharuddin? More crucially, *what* was he? Those are precisely the questions that, as the end credits roll after 132 minutes of run-time, remain unanswered, feels......

Rediff News

Dr Reddyrsquo

News for Dr Reddyrsquo

Covid vaccine could cost up to Rs 1000 in private market

Expert panel seeks more data on Sputnik V Covid vaccine

Sputnik V vaccine may be added to India's Covid armoury soon

COVID-19 vaccines likely to have longer shelf life

Cipla to price Remdesivir for Covid-19 under Rs 5,000

Upper-teens EPS growth likely for Gland Pharma in next two financial yrs

Lower input costs may aid pharma firms' Q2 margins

BSE 100 companies boost R&D, innovation challenges persist

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

Pricing challenge in US biz, rich valuations may weigh on pharma stocks

Review: Azhar is a bland, badly-set souffl of Bollywood tropes without a soul

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS